Measuring Treatment Response in Progressive Multiple Sclerosis—Considerations for Adapting to an Era of Multiple Treatment Options

Oh, 2018, Multiple sclerosis: Clinical aspects, Curr. Opin. Neurol., 31, 752, 10.1097/WCO.0000000000000622

Miller, 2007, Primary-progressive multiple sclerosis, Lancet Neurol., 6, 903, 10.1016/S1474-4422(07)70243-0

Kister, 2013, Natural History of Multiple Sclerosis Symptoms, Int. J. MS Care, 15, 146, 10.7224/1537-2073.2012-053

Tutuncu, 2012, Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis, Mult. Scler. J., 19, 188, 10.1177/1352458512451510

Weinshenker, 1989, The natural history of multiple sclerosis: A geographically based study. I. Clinical course and disability, Brain, 112, 133, 10.1093/brain/112.1.133

Confavreux, 2003, Early clinical predictors and progression of irreversible disability in multiple sclerosis: An amnesic process, Brain, 126, 770, 10.1093/brain/awg081

Runmarker, 1993, Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up, Brain, 116, 117, 10.1093/brain/116.1.117

Bsteh, G., Ehling, R., Lutterotti, A., Hegen, H., Di Pauli, F., Auer, M., Deisenhammer, F., Reindl, M., and Berger, T. (2016). Long Term Clinical Prognostic Factors in Relapsing-Remitting Multiple Sclerosis: Insights from a 10-Year Observational Study. PLoS ONE, 11.

Scott, 2014, Relapsing multiple sclerosis patients treated with disease modifying therapy exhibit highly variable disease progression: A predictive model, Clin. Neurol. Neurosurg., 127, 86, 10.1016/j.clineuro.2014.09.008

Brown, 2019, Association of Initial Disease-Modifying Therapy with Later Conversion to Secondary Progressive Multiple Sclerosis, JAMA, 321, 175, 10.1001/jama.2018.20588

Montalban, 2017, Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis, N. Engl. J. Med., 376, 209, 10.1056/NEJMoa1606468

Kappos, 2018, Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): A double-blind, randomised, phase 3 study, Lancet, 391, 1263, 10.1016/S0140-6736(18)30475-6

Kurtzke, 1983, Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS), Neurology, 33, 1444, 10.1212/WNL.33.11.1444

Hawker, 2009, Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial, Ann. Neurol., 66, 460, 10.1002/ana.21867

Kappos, 1998, Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS, Lancet, 352, 1491, 10.1016/S0140-6736(98)10039-9

Wolinsky, 2007, Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial, Ann. Neurol., 61, 14, 10.1002/ana.21079

SPECTRIMS Study Group (2001). Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MSSG. Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results. Neurology, 56, 1496–1504.

Lublin, 2016, Oral fingolimod in primary progressive multiple sclerosis (INFORMS): A phase 3, randomised, double-blind, placebo-controlled trial, Lancet, 387, 1075, 10.1016/S0140-6736(15)01314-8

Lublin, 2014, Defining the clinical course of multiple sclerosis: The 2013 revisions, Neurology, 83, 278, 10.1212/WNL.0000000000000560

Hartung, 2002, Mitoxantrone in progressive multiple sclerosis: A placebo-controlled, double-blind, randomised, multicentre trial, Lancet, 360, 2018, 10.1016/S0140-6736(02)12023-X

Lepore, 2020, Detection of disability worsening in relapsing-remitting multiple sclerosis patients: A real-world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register, Eur. J. Neurol., 28, 567, 10.1111/ene.14589

Kappos, 2017, Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study, Mult. Scler. J., 24, 963, 10.1177/1352458517709619

Kremenchutzky, 2006, The natural history of multiple sclerosis: A geographically based study 9: Observations on the progressive phase of the disease, Brain, 129, 584, 10.1093/brain/awh721

Cinar, 2018, What We Learned from The History of Multiple Sclerosis Measurement: Expanded Disability Status Scale, Noro. Psikiyatr. Ars., 55, S69

Sharrack, 1999, The psychometric properties of clinical rating scales used in multiple sclerosis, Brain, 122, 141, 10.1093/brain/122.1.141

Cadavid, 2010, Responsiveness of the Expanded Disability Status Scale (EDSS) to disease progression and therapeutic intervention in progressive forms of multiple sclerosis, Rev. Neurol., 51, 321

Hyland, 2011, Challenges to clinical trials in multiple sclerosis: Outcome measures in the era of disease-modifying drugs, Curr. Opin. Neurol., 24, 255, 10.1097/WCO.0b013e3283460542

Kragt, 2008, Responsiveness and predictive value of EDSS and MSFC in primary progressive MS, Neurology, 70, 1084, 10.1212/01.wnl.0000288179.86056.e1

Brissart, 2010, Integration of Cognitive Impairment in the Expanded Disability Status Scale of 215 Patients with Multiple Sclerosis, Eur. Neurol., 64, 345, 10.1159/000322140

Amato, 1988, Interrater Reliability in Assessing Functional Systems and Disability on the Kurtzke Scale in Multiple Sclerosis, Arch. Neurol., 45, 746, 10.1001/archneur.1988.00520310052017

Goodkin, 1992, Inter- and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS), Neurology, 42, 859, 10.1212/WNL.42.4.859

Noseworthy, 1990, Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group, Neurology, 40, 971, 10.1212/WNL.40.6.971

Feng, 2014, Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis, BMC Neurol., 14, 58, 10.1186/1471-2377-14-58

Kieseier, 2012, Assessing walking disability in multiple sclerosis, Mult. Scler. J., 18, 914, 10.1177/1352458512444498

Motl, 2017, Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis, Mult. Scler. J., 23, 704, 10.1177/1352458517690823

Bosma, 2011, Clinical scales in progressive MS: Predicting long-term disability, Mult. Scler. J., 18, 345, 10.1177/1352458511419880

Orbach, R., Zhao, Z., Wang, Y.-C., O’Neill, G., and Cadavid, D. (2012). Comparison of Disease Activity in SPMS and PPMS in the Context of Multicenter Clinical Trials. PLoS ONE, 7.

Pace, 2011, Comparison of the Timed 25-Foot and the 100-Meter Walk as Performance Measures in Multiple Sclerosis, Neurorehabilit. Neural Repair, 25, 672, 10.1177/1545968310397204

Kapoor, 2018, Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): A phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension, Lancet Neurol., 17, 405, 10.1016/S1474-4422(18)30069-3

Kaufman, 2000, The significant change for the Timed 25-foot Walk in the multiple sclerosis functional composite, Mult. Scler. J., 6, 286, 10.1177/135245850000600411

Coleman, 2011, Minimally important clinical difference of the Timed 25-Foot Walk Test: Results from a randomized controlled trial in patients with multiple sclerosis, Curr. Med. Res. Opin., 28, 49, 10.1185/03007995.2011.639752

Kragt, 2006, Clinical impact of 20% worsening on Timed 25-foot Walk and 9-hole Peg Test in multiple sclerosis, Mult. Scler. J., 12, 594, 10.1177/1352458506070768

Bosma, 2010, Progression on the Multiple Sclerosis Functional Composite in multiple sclerosis: What is the optimal cut-off for the three components?, Mult. Scler. J., 16, 862, 10.1177/1352458510370464

Hobart, 2013, Timed 25-Foot Walk: Direct evidence that improving 20% or greater is clinically meaningful in MS, Neurology, 80, 1509, 10.1212/WNL.0b013e31828cf7f3

Koch, 2019, Clinical outcome measures in SPMS trials: An analysis of the IMPACT and ASCEND original trial data sets, Mult. Scler. J., 26, 1540, 10.1177/1352458519876701

Sikes, 2019, Quantitative Synthesis of Timed 25-Foot Walk Performance in Multiple Sclerosis, Arch. Phys. Med. Rehabil., 101, 524, 10.1016/j.apmr.2019.08.488

Goldman, 2019, Evaluation of multiple sclerosis disability outcome measures using pooled clinical trial data, Neurology, 93, e1921, 10.1212/WNL.0000000000008519

Cutter, 1999, Development of a multiple sclerosis functional composite as a clinical trial outcome measure, Brain, 122, 871, 10.1093/brain/122.5.871

Goodkin, 1988, Upper extremity function in multiple sclerosis: Improving assessment sensitivity with box-and-block and nine-hole peg tests, Arch. Phys. Med. Rehabil., 69, 850

Bertoni, 2015, Unilateral and bilateral upper limb dysfunction at body functions, activity and participation levels in people with multiple sclerosis, Mult. Scler. J., 21, 1566, 10.1177/1352458514567553

Lamers, 2015, Associations of Upper Limb Disability Measures on Different Levels of the International Classification of Functioning, Disability and Health in People with Multiple Sclerosis, Phys. Ther., 95, 65, 10.2522/ptj.20130588

Solaro, 2019, Clinical correlates of 9-hole peg test in a large population of people with multiple sclerosis, Mult. Scler. Relat. Disord., 30, 1, 10.1016/j.msard.2019.01.043

Koivisto, 2007, The reliability of the MSFC and its components, Acta Neurol. Scand., 117, 421, 10.1111/j.1600-0404.2007.00972.x

Feys, 2017, The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis, Mult. Scler. J., 23, 711, 10.1177/1352458517690824

Tombaugh, 2006, A comprehensive review of the Paced Auditory Serial Addition Test (PASAT), Arch. Clin. Neuropsychol., 21, 53, 10.1016/j.acn.2005.07.006

Gronwall, 1977, Paced Auditory Serial-Addition Task: A Measure of Recovery from Concussion, Percept. Mot. Ski., 44, 367, 10.2466/pms.1977.44.2.367

Rudick, 2002, The multiple sclerosis functional composite: A new clinical outcome measure for multiple sderosis trials, Mult. Scler. J., 8, 359, 10.1191/1352458502ms845oa

Brooks, 2011, Paced auditory serial addition test (PASAT): A very difficult test even for individuals with high intellectual capability, Arq. Neuro-Psiquiatria, 69, 482, 10.1590/S0004-282X2011000400014

Cleynhens, 2014, The Symbol Digit Modalities Test as sentinel test for cognitive impairment in multiple sclerosis, Eur. J. Neurol., 21, 1219-e72

Kalb, 2018, Recommendations for cognitive screening and management in multiple sclerosis care, Mult. Scler. J., 24, 1665, 10.1177/1352458518803785

Strober, 2018, Symbol Digit Modalities Test: A valid clinical trial endpoint for measuring cognition in multiple sclerosis, Mult. Scler. J., 25, 1781, 10.1177/1352458518808204

Ontaneda, 2012, Revisiting the Multiple Sclerosis Functional Composite: Proceedings from the National Multiple Sclerosis Society (NMSS) Task Force on Clinical Disability Measures, Mult. Scler. J., 18, 1074, 10.1177/1352458512451512

Querol, 2015, A one-year follow-up study of the Symbol Digit Modalities Test (SDMT) and the Paced Auditory Serial Addition Test (PASAT) in relapsing-remitting multiple sclerosis: An appraisal of comparative longitudinal sensitivity, BMC Neurol., 15, 1

Benedict, 2021, Siponimod and cognition in secondary progressive multiple sclerosis: EXPAND secondary analyses, Neurology, 96, e376, 10.1212/WNL.0000000000011275

Benedict, 2017, Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis, Mult. Scler. J., 23, 721, 10.1177/1352458517690821

Drake, 2009, Psychometrics and normative data for the Multiple Sclerosis Functional Composite: Replacing the PASAT with the Symbol Digit Modalities Test, Mult. Scler. J., 16, 228, 10.1177/1352458509354552

Kiely, 2014, The Symbol Digit Modalities Test: Normative Data from a Large Nationally Representative Sample of Australians, Arch. Clin. Neuropsychol., 29, 767, 10.1093/arclin/acu055

Roar, 2016, Practice effect in Symbol Digit Modalities Test in multiple sclerosis patients treated with natalizumab, Mult. Scler. Relat. Disord., 10, 116, 10.1016/j.msard.2016.09.009

Galetta, 2013, Measures of visual pathway structure and function in MS: Clinical usefulness and role for MS trials, Mult. Scler. Relat. Disord., 2, 172, 10.1016/j.msard.2012.12.004

Balcer, 2017, Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis, Mult. Scler. J., 23, 734, 10.1177/1352458517690822

Talman, 2010, Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis, Ann. Neurol., 67, 749, 10.1002/ana.22005

Walter, 2012, Ganglion Cell Loss in Relation to Visual Disability in Multiple Sclerosis, Ophthalmology, 119, 1250, 10.1016/j.ophtha.2011.11.032

Reich, 2009, Damage to the Optic Radiation in Multiple Sclerosis Is Associated With Retinal Injury and Visual Disability, Arch. Neurol., 66, 998, 10.1001/archneurol.2009.107

Cohen, 2002, Benefit of interferon beta-1a on MSFC progression in secondary progressive MS, Neurology, 59, 679, 10.1212/WNL.59.5.679

Balcer, 2000, New low-contrast vision charts: Reliability and test characteristics in patients with multiple sclerosis, Mult. Scler., 6, 163, 10.1177/135245850000600305

Balcer, 2012, Low-contrast acuity measures visual improvement in phase 3 trial of natalizumab in relapsing MS, J. Neurol. Sci., 318, 119, 10.1016/j.jns.2012.03.009

Beck, 2007, Visual Acuity as an Outcome Measure in Clinical Trials of Retinal Diseases, Ophthalmology, 114, 1804, 10.1016/j.ophtha.2007.06.047

Jakimovski, 2021, Visual deficits and cognitive assessment of multiple sclerosis: Confounder, correlate, or both?, J. Neurol., 268, 2578, 10.1007/s00415-021-10437-5

Balcer, 2014, Vision and vision-related outcome measures in multiple sclerosis, Brain, 138, 11, 10.1093/brain/awu335

Sipe, 1984, A neurologic rating scale (NRS) for use in multiple sclerosis, Neurology, 34, 1368, 10.1212/WNL.34.10.1368

Koziol, 1999, Responsiveness of the Scripps neurologic rating scale during a multiple sclerosis clinical trial, Can. J. Neurol. Sci. J. Can. Sci. Neurol., 26, 283, 10.1017/S0317167100000391

Sipe, 1994, Cladribine in treatment of chronic progressive multiple sclerosis, Lancet, 344, 9, 10.1016/S0140-6736(94)91046-4

Eshaghi, 2018, Deep gray matter volume loss drives disability worsening in multiple sclerosis, Ann. Neurol., 83, 210, 10.1002/ana.25145

Stromillo, 2016, Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis, J. Neurol. Neurosurg. Psychiatry, 87, 93

Eijlers, 2019, Cortical atrophy accelerates as cognitive decline worsens in multiple sclerosis, Neurology, 93, e1348, 10.1212/WNL.0000000000008198

Duning, 2005, Dehydration confounds the assessment of brain atrophy, Neurology, 64, 548, 10.1212/01.WNL.0000150542.16969.CC

Nakamura, 2015, Diurnal fluctuations in brain volume: Statistical analyses of MRI from large populations, NeuroImage, 118, 126, 10.1016/j.neuroimage.2015.05.077

Enzinger, 2005, Risk factors for progression of brain atrophy in aging: Six-year follow-up of normal subjects, Neurology, 64, 1704, 10.1212/01.WNL.0000161871.83614.BB

Airas, 2014, Clinical relevance of brain volume measures in multiple sclerosis, CNS Drugs, 28, 147, 10.1007/s40263-014-0140-z

Zivadinov, 2016, Autoimmune Comorbidities Are Associated with Brain Injury in Multiple Sclerosis, Am. J. Neuroradiol., 37, 1010, 10.3174/ajnr.A4681

Zivadinov, 2008, Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis, Neurology, 71, 136, 10.1212/01.wnl.0000316810.01120.05

Song, 2019, Correlation between EDSS scores and cervical spinal cord atrophy at 3T MRI in multiple sclerosis: A systematic review and meta-analysis, Mult. Scler. Relat. Disord., 37, 101426, 10.1016/j.msard.2019.101426

Casserly, 2018, Spinal Cord Atrophy in Multiple Sclerosis: A Systematic Review and Meta-Analysis, J. Neuroimaging, 28, 556, 10.1111/jon.12553

Moccia, M., Ruggieri, S., Ianniello, A., Toosy, A., Pozzilli, C., and Ciccarelli, O. (2019). Advances in spinal cord imaging in multiple sclerosis. Ther. Adv. Neurol. Disord., 12.

Rudick, 1997, Recommendations from the national multiple sclerosis society clinical outcomes assessment task force, Ann. Neurol., 42, 379, 10.1002/ana.410420318

Fischer, 1999, The Multiple Sclerosis Functional Composite Measure (MSFC): An integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force, Mult. Scler. J., 5, 244, 10.1177/135245859900500409

Cadavid, 2016, The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis, Mult. Scler. J., 23, 94, 10.1177/1352458516638941

Inojosa, 2020, Clinical outcome measures in multiple sclerosis: A review, Autoimmun. Rev., 19, 102512, 10.1016/j.autrev.2020.102512

Turkistani, 2016, Evaluation of the Expanded Disability Status Scale and the Multiple Sclerosis Functional Composite as clinical endpoints in multiple sclerosis clinical trials: Quantitative meta-analyses, Curr. Med. Res. Opin., 32, 1969, 10.1080/03007995.2016.1222516

Bosma, 2009, The search for responsive clinical endpoints in primary progressive multiple sclerosis, Mult. Scler. J., 15, 715, 10.1177/1352458509102626

Wolinsky, 2018, Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial, Ann. Neurol., 84, 527, 10.1002/ana.25313

Hegen, H., Bsteh, G., and Berger, T. (2018). ‘No evidence of disease activity’—Is it an appropriate surrogate in multiple sclerosis?. Eur. J. Neurol., 25.

Goldberg, 2014, Individual and Composite Study Endpoints: Separating the Wheat from the Chaff, Am. J. Med., 127, 379, 10.1016/j.amjmed.2014.01.011

Lorscheider, 2016, Defining secondary progressive multiple sclerosis, Brain, 139, 2395, 10.1093/brain/aww173

Krajnc, 2021, Clinical and Paraclinical Biomarkers and the Hitches to Assess Conversion to Secondary Progressive Multiple Sclerosis: A Systematic Review, Front. Neurol., 12, 666868, 10.3389/fneur.2021.666868

Hohol, 1999, Disease steps in multiple sclerosis: A longitudinal study comparing disease steps and EDSS to evaluate disease progression, Mult. Scler. J., 5, 349, 10.1177/135245859900500508

Ravnborg, 2005, Responsiveness of the Multiple Sclerosis Impairment Scale in comparison with the Expanded Disability Status Scale, Mult. Scler. J., 11, 81, 10.1191/1352458505ms1120oa

University of California SFMSET, Cree BAC, Hollenbach, J.A., Bove, R., Kirkish, G., Sacco, S., Caverzasi, E., Bischof, A., Gundel, T., and Zhu, A.H. (2019). Silent progression in disease activity-free relapsing multiple sclerosis. Ann. Neurol., 85, 653–666.

Benedict, 2020, Recovery of cognitive function after relapse in multiple sclerosis, Mult. Scler. J., 27, 71, 10.1177/1352458519898108

Kalinowski, A., Cutter, G., Bozinov, N., Hinman, J.A., Hittle, M., Motl, R., Odden, M., and Nelson, L.M. (2021). The timed 25-foot walk in a large cohort of multiple sclerosis patients. Mult. Scler. J., 13524585211017013.

Goldman, 2013, Clinically meaningful performance benchmarks in MS: Timed 25-Foot Walk and the real world, Neurology, 81, 1856, 10.1212/01.wnl.0000436065.97642.d2

Ferraro, 2019, Plasma neurofilaments correlate with disability in progressive multiple sclerosis patients, Acta Neurol. Scand., 141, 16, 10.1111/ane.13152

Ebers, 2008, Disability as an outcome in MS clinical trials, Neurology, 71, 624, 10.1212/01.wnl.0000313034.46883.16

Koch, 2020, Reliability of Outcome Measures in Clinical Trials in Secondary Progressive Multiple Sclerosis, Neurology, 96, e111

Kalincik, 2021, Has the Time Come to Revisit Our Standard Measures of Disability Progression in Multiple Sclerosis?, Neurology, 96, 12, 10.1212/WNL.0000000000011120

Tourbah, 2016, MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study, Mult. Scler. J., 22, 1719, 10.1177/1352458516667568

Liu, 2000, Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: Effects of heterogeneity of disease course in placebo cohorts, J. Neurol. Neurosurg. Psychiatry, 68, 450, 10.1136/jnnp.68.4.450

Kalincik, 2015, Defining reliable disability outcomes in multiple sclerosis, Brain, 138, 3287, 10.1093/brain/awv258

Ontaneda, 2017, Clinical outcome measures for progressive MS trials, Mult. Scler. J., 23, 1627, 10.1177/1352458517729465

Kappos, 2020, Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials, JAMA Neurol., 77, 1132, 10.1001/jamaneurol.2020.1568

Saidha, 2015, Optical coherence tomography reflects brain atrophy in multiple sclerosis: A four-year study, Ann. Neurol., 78, 801, 10.1002/ana.24487

Saidha, 2013, Relationships between retinal axonal and neuronal measures and global central nervous system pathology in multiple sclerosis, JAMA Neurol., 70, 34, 10.1001/jamaneurol.2013.573

Bsteh, 2017, Peripapillary retinal nerve fibre layer as measured by optical coherence tomography is a prognostic biomarker not only for physical but also for cognitive disability progression in multiple sclerosis, Mult. Scler. J., 25, 196, 10.1177/1352458517740216

Arnow, 2016, Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: A cohort study, Lancet Neurol., 15, 574, 10.1016/S1474-4422(16)00068-5

Bsteh, 2019, Peripapillary retinal nerve fibre layer thinning rate as a biomarker discriminating stable and progressing relapsing–remitting multiple sclerosis, Eur. J. Neurol., 26, 865, 10.1111/ene.13897

Bsteh, 2020, Macular ganglion cell–inner plexiform layer thinning as a biomarker of disability progression in relapsing multiple sclerosis, Mult. Scler. J., 27, 684, 10.1177/1352458520935724

Bowd, 2016, Estimating Optical Coherence Tomography Structural Measurement Floors to Improve Detection of Progression in Advanced Glaucoma, Am. J. Ophthalmol., 175, 37, 10.1016/j.ajo.2016.11.010

Disanto, 2017, Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis, Ann. Neurol., 81, 857, 10.1002/ana.24954

Novakova, 2017, Monitoring disease activity in multiple sclerosis using serum neurofilament light protein, Neurology, 89, 2230, 10.1212/WNL.0000000000004683

Damasceno, 2019, Clinical and MRI correlates of CSF neurofilament light chain levels in relapsing and progressive MS, Mult. Scler. Relat. Disord., 30, 149, 10.1016/j.msard.2019.02.004

Barro, 2018, Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis, Brain, 141, 2382, 10.1093/brain/awy154

Kuhle, 2019, Blood neurofilament light chain as a biomarker of MS disease activity and treatment response, Neurology, 92, e1007, 10.1212/WNL.0000000000007032

Sellebjerg, 2018, Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis, Mult. Scler. J., 25, 1444, 10.1177/1352458518794308

Kapoor, 2020, Serum neurofilament light as a biomarker in progressive multiple sclerosis, Neurology, 95, 436, 10.1212/WNL.0000000000010346

Altmann, 2008, Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis, Neurology, 72, 595, 10.1212/01.wnl.0000335765.55346.fc

Delcoigne, 2020, Blood neurofilament light levels segregate treatment effects in multiple sclerosis, Neurology, 94, e1201, 10.1212/WNL.0000000000009097

Kosa, 2016, Development of a Sensitive Outcome for Economical Drug Screening for Progressive Multiple Sclerosis Treatment, Front. Neurol., 7, 131, 10.3389/fneur.2016.00131

Khurana, 2017, Patient-reported outcomes in multiple sclerosis: A systematic comparison of available measures, Eur. J. Neurol., 24, 1099, 10.1111/ene.13339